The HDAC8 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HDAC8 gene in the human PaTu 8988t pancreatic ductal adenocarcinoma cell line. This polyclonal pool provides a heterogeneous loss-of-function model for studying HDAC8 biology, capturing diverse editing outcomes and minimizing clonal artifacts.
The PaTu 8988t cell line was derived from a liver metastasis of a pancreatic ductal adenocarcinoma, making it a clinically relevant model of advanced metastatic pancreatic cancer. It exhibits aggressive proliferation, invasive capacity, and resistance to apoptosis, faithfully recapitulating key features of late-stage disease and offering an ideal background for studying drivers of metastasis.
HDAC8 is a class I histone deacetylase that regulates transcription, cell cycle progression, and apoptosis by deacetylating histone and non-histone substrates. Upstream regulators include MYC, TP53, NF-??B, and SP1, as well as the kinases PKA and ERK. Downstream, HDAC8 deacetylates p53, impairing its transcriptional activity and reducing expression of the CDK inhibitor p21, thus promoting proliferation. It also deacetylates cortactin, enhancing actin dynamics and cell motility. HDAC8 interacts with co-repressors SMRT/NCoR and factors such as HSP70, CREBBP, and MTA1. Through histone H3/H4 deacetylation, it represses genes including E-cadherin, contributing to epithelial-mesenchymal transition.
In pancreatic cancer, HDAC8 exerts dual oncogenic functions: deacetylation of p53 suppresses p21-mediated cell cycle arrest and apoptosis, while cortactin deacetylation fuels migration and invasion. The HDAC8 knockout in PaTu 8988t thus provides a powerful tool to dissect these mechanisms. Loss of HDAC8 is anticipated to restore p53-dependent tumor suppression and impair motility, offering insights into pathway rewiring and potential therapeutic targets. The polyclonal nature of the knockout pool ensures a more robust and representative system compared to single-cell clones.
These polyclonal knockout cells are suitable for a range of applications, including functional genomics, epigenetic drug screening, and metastasis research. Typical experiments include confirmation of HDAC8 disruption by western blot, RT-qPCR analysis of downstream targets (e.g., p21, E-cadherin), proliferation and apoptosis assays (MTT, Annexin V), Transwell migration/invasion assays, acetylated histone profiling, ChIP-qPCR, and RNA-seq. They are also appropriate for target validation and inhibitor testing. For further details, please contact Ascent Research.
